1. Pink Sheet
  2. >>R&D
  3. >>Clinical Trials

Clinical Trials In China: As US Lawmakers Consider Crackdown, Here Are The Implications

 
• By Sarah Karlin-Smith

If the US Congress continues to target trials at Chinese military hospitals, the impact could be relatively small, while a broader focus could upend multinational development programs. 

map of China
Some US lawmakers want to crack down on clinical trials conducted in China. • Source: Shutterstock

A bipartisan group of US lawmakers’ concerns about clinical trials conducted at Chinese military hospitals likely would have a minimal impact on late-stage drug development if the attention translated to legislation cracking down on the US Food and Drug Administration’s ability to review applications with that data.

Key Takeaways

  • Only about 1% to 4% of the sites currently qualified and conducting Phase III research in China are military hospitals.

Lawmakers recently raised concerns about US pharma company collaborations with the hospitals. (Also see "Beyond BIOSECURE: Lawmakers Flag US...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

More from R&D

UK Looks To Auto-Match NHS Patients With Clinical Trials To Boost Recruitment

 
• By Vibha Sharma

The UK government is making it easier for millions of people to participate in clinical trials and is boosting transparency around how studies are delivered across the National Health Service.

Global Guideline Signals ‘Paradigm Shift’ For Pregnant And Breastfeeding Women, Says EMA

 
• By Anabel Costa-Ferreira

The European Medicines Agency expects the International Council for Harmonization’s new guideline will help address the critical lack of data on the use of medicinal products in pregnant and breastfeeding populations.

Profit-Sharing AI Model Proposed To Boost Korean Drug R&D

 
• By Jung Won Shin

A differentiated profit-sharing model to accelerate the use of AI in drug development using clinical and patient data is being proposed in South Korea, but the idea faces multiple practical challenges